JUVE Patent

Jin Ooi

Kirkland & Ellis

Kirkland & Ellis International LLP
EC3A 8AF London
United Kingdom
phone_icon Created with Sketch. +44 20 7953 2638
envelope_icon Created with Sketch. jin.ooi@kirkland.com


Pharmaceuticals, Biotechnology, Chemistry, Medical Devices, Engineering, Materials, Mechanical Engineering, Automation & Robotics

About Jin Ooi

Jin Ooi is a partner in the London office of Kirkland & Ellis International LLP. He is experienced in patent litigation and counselling (including on complex damages inquiries) mainly in the pharmaceutical and life sciences field (second medical use, biosimilars, small molecules, DNA sequencing, vaccines, transgenic animal platforms for antibody discovery), and in the consumer products sector (shaving razors, potentially reduced-risk products including tobacco heating and vapour products, dishwashing tablets, coffee pods and capsules).

He is also experienced in litigating and arbitrating trade secrets disputes in the medical devices (bone cements), tech (LNG carriers) and aviation sector (airplane components, airport businesses), in addition to handling antitrust claims (cathode ray tubes, lithium ion batteries, forklift gas).

His clients have included Pfizer, Novartis, Regeneron, British American Tobacco, Samsung, Biomet and Procter & Gamble. Jin’s cases are often multi-jurisdictional requiring significant cross-border coordination across multiple forums.

His recent recognitions include:

The Legal 500 UK, 2021 (Intellectual Property: Patents): ’Powerhouse’ partner Jin Ooi is another noteworthy name; ‘Jin Ooi’s knowledge of second medical use issues is market leading’; ‘Jin Ooi is a powerhouse and is always available and highly responsive. He is a master of detail and able to clearly explain complex issues’.

The Legal 500 UK, 2021 (Life Sciences and Healthcare): Litigator Jin Ooi has a pharmacology background and handles cross-border IP-related cases for a wide range of pharma clients; ‘Jin Ooi is very knowledgeable and very good at simplifying complicated issues’; ‘Jin Ooi has an impressive knowledge of the case law, especially second medical use cases. He is very perceptive and appreciative of input and takes input in order to lead a team effort’.

The Legal 500 UK, 2020 (Intellectual Property): ‘Jin Ooi is renowned for his ability to master knotty issues and has famed round-the-clock responsiveness’; ‘Jin Ooi is brilliant on detail and in plotting out the future stages of litigation’.

The Legal 500 UK, 2020 (Pharmaceuticals and Biotechnology): ‘Jin Ooi is an associate to watch out for. He has a keen attention to detail and will rapidly deploy his considerable knowledge of the facts and related case law to examine the situation to hand. He has a natural curiosity and strong intellect which lends well to valuable insights and contributions. He is also calm and meticulously organised which ensures the smooth and quick development of a case, no matter how many moving and complex parts there are’.

Prior to joining Kirkland, Jin worked at Allen & Overy LLP in London for 4 years and before that Corrs Chambers Westgarth in Sydney for 3½ years. In recognition of his work in Australia, Jin was among a select few young lawyers awarded the 2014 Lawyers Weekly 30 Under 30 Awards, and a finalist in two categories in the 2015 Awards. His dual qualifications in law (1st class degree) and pharmacology give him a special insight into, and understanding of, his clients’ legal needs and commercial and regulatory imperatives.


  • Next Generation Partner in both “Intellectual Property: Patents” and “Life Sciences and Healthcare” in the 2021 edition of The Legal 500 UK
  • Rising Star in the 2020/2021 edition of MIP IP Stars
  • Rising Star in Pharmaceuticals and Biotechnology in the 2020 edition of The Legal 500 UK
  • Finalist, 2015 Lawyers Weekly 30 Under 30 Awards, Australia
  • Winner, 2014 Lawyers Weekly 30 Under 30 Awards, Australia


  • “Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides, 2019
  • “UK Patent Law: Hot Topics of 2018 and What’s Ahead”, Law360, 2019
  • “Actavis v Eli Lilly: outcomes”, IPPro, 2018
  • "Book review: Intellectual Property in Australia", The IPKat, 2017
  • "Applying Cartier v. BSkyB to UK life sciences patents", Law360, 2016
  • "Caught in the middle: ISPs face blocking orders after Cartier case", Intellectual Property Magazine, 2016
  • "The utility of the Cartier case in the life sciences context", Intellectual Property Magazine, 2016
  • "The International Arbitration Review (Chapter: Australia)" (3rd, 4th and 5th eds), Law Business Research, 2012-2014

More experts at Kirkland & Ellis